A Life Science focused investment fund based in China serves as an internal funding vehicle for a major medical group.  The firm primarily considers investments based in China or has a significant China nexus, for example, the company must have a principal market in China, or R&D/manufacturing/sales in China. The fund prefers to follow and take minority stakes. Investment size varies but typically ranges from US$1-4 million. The fund prefers business models that are marketing/sales oriented (vs. technology oriented). The fund is actively seeking new investment opportunities.

Currently the firm is looking for innovative antibiotics or alternatives to antibiotics in human health, animal health, and agriculture. For the stage of development, the fund seeks products that are able to enter the market within 2 years post investment.

The firm seeks an experienced management team that “has done it before.” The fund will consider US-based companies as long as the China nexus criteria is met. The firm seeks to make minority investment and typically requires China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Virginia focuses on healthcare IT and diagnostics. The firm primarily invests in the growth stage at the series A or B round, though if investing early, the firm would be part of a syndicate. The firm typically invests around $1M-$15M into early companies, and $10M-$30M into growth stage companies. The firm seeks to make 10-15 new investments within the next year. The firm focuses on companies based in USA and Canada due to practical matters, though may be open to investments on a global level.

The firm has a primary focus in healthcare IT, particularly in EMR companies, analytics, and any next generation IT tools for enterprise or ambulatory settings. The firm is also focused in tools and diagnostics, specifically in 510K genomics diagnostics, though is open to any kind of new diagnostic tool or test. The firm is also now seeking therapeutic opportunities. The firm currently does not have interest in therapeutics or medical technology. The firm prefers companies with a commercialized product that is producing revenue, though does not have a revenue requirement and may be open to clinical stage products.

The firm primarily invests in growth stage companies where 80% of their invested companies have revenue with a product looking to expand in the market and 20% of invested companies at the pre-revenue, close to commercialization stage. The firm typically invests in pre-revenue companies when the technology is close to commercialization (i.e. steps away from approval) and/or when the company has a strong management team with members the firm has known from before. The firm does not have a management team requirement and will take a board seat depending on the size and ownership of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture and growth capital firm provides expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies. The firm is based in Geneva, Switzerland, and focuses on early to growth and expansion stage including spin-offs and restarts. The firm is currently making new investments from a €250 million fund closed in 2016. The firm prefers to be the lead investor and possibly co-lead. The firm seeks to allocate €7-15 million (in equity) per company through subsequent rounds of investment. The firm seeks to invest in companies that are based in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm seeks to invest in medical devices, and digital health. The firm is opportunistic in terms of subsectors and indications. Medical devices with a therapeutic focus are of high interest. The firm seeks growth stage companies with early sales or with products that, at minimum, have regulatory approval (CE mark) and compelling clinical data.

The firm requests a board seat in each portfolio company and generally holds a significant minority stake. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital firm based in Texas raised a new fund in 2016. The firm looks to make Series A equity investments ranging from $250,000 to $1.5 million in the initial round with up to $3 million reserved for follow on financing. Only on a case-by-case basis will the firm look to make seed investments. The firm focuses on companies in the United States and may also consider exceptional opportunities in Canada.

The firm is interested in investing in companies in the Medical Device, Diagnostics and Therapeutics spaces. The firm has a much stronger focus on devices with approximately 75% of the firm’s investments to date falling into those sectors. For Medical Devices the firm generally looks for companies that have either an early prototype or proof-of-concept data to support them. The firm is also currently interested in companies working with diagnostic devices and is not looking for companies in oncology. For therapeutics companies the firm generally makes investment in pre-clinical assets and will evaluate opportunities on a case-by-case basis.

The firm seeks privately held companies and maintains very positive and productive working relationships with its portfolio companies, providing as much assistance as needed. The firm is much more open to taking significant scientific and technical risk as opposed to sales and marketing challenges.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A digital healthcare-focused seed fund was founded in 2015 and is based in the US Midwest. The firm typically acts as the lead investor in a priced equity round. The firm’s team is made up of three partners and has collectively invested in more than a dozen digital health companies as individual investors. The fund currently focuses on opportunities in the Upper Midwest, with a target investment in the $500,000 range.

The firm seeks to fund companies working in the digital health space, including health data management systems, patient-physician interface, cloud computing, and software-enabled devices.

The firm looks for teams that have some healthcare experience in senior management. The firm prefers a strong founding team, possessing varied skills that include technical expertise, sales, operational and marketing experience in senior leadership. After investment, the firm actively advise portfolio companies in various ways, including helping with introductions to health system customers, building teams and advising on operations and management. As such the firm will usually hold a seat on the board along with the founders.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm headquartered in China provides venture capital and growth capital to early-stage companies across various industries, including life sciences, Internet, software, and high technology sectors (i.e. drones). The firm is interested in all types of life science companies except drug development. The allocation size will vary, but the firm has the capability to allocate up to $40 million per company, depending on the opportunity. The investment is typically in form of equity, but convertible loan will be considered as well. The firm has an emphasis on technologies and products, and it is currently seeking new investment opportunities globally.

The firm is currently seeking to invest in medical device, diagnostics, biotech R&D services and healthcare IT sectors. The firm is very opportunistic in terms of subsectors and indications. Currently the firm will not invest in companies targeting drug development. The firm will consider companies at all stages of development, from pre-clinical stage all through to commercial stage; however, the firm prefers companies in the business proven stage, where the product is on the market and may already have customer feedback.

The firm primarily invests in early-stage private companies. The firm does not have specific requirements for companies’ management team or revenues. The firm will take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An evergreen fund backed by a family office is focused on seed to later-stage companies building infrastructure and value chains around big data, including but not limited to health and life science data. Initial investment sizes fall within a wide range. Additional capital for follow-on investments is available for portfolio companies. Along with capital, the firm also provides access to their Asian network for later-stage companies needing market expansion (once all other aspects of the company’s business have been resolved). There is not a requirement for a board seat along with investments.  The fund is focused on U.S. companies (with a focus on Silicon Valley), but will consider companies globally.

The firm invests in companies that are creating solutions to close the data feedback loop, including capturing data, analytics and instruments/robotics. The firm is interested in medical devices, diagnostics and healthcare IT products, with addressable markets of at least $1B. In the diagnostics field, m-health devices and genomics are of particular interest. The firm is open to all sub-sectors of health IT including consumer-facing hardware/software, data collection/management and data analytics. The firm will invest in medical devices and diagnostics that require FDA approval, with 510K regulatory pathway being the most common, although devices/services that require different regulatory pathways will also be considered. Companies developing hardware or robotics that automate scientific life science experiments are also of interest.

There are no formal requirements for management teams, but management teams with experience commercializing products are preferred.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com